INSMED Inc SEC Filings

Insmed has a shareholder planning to sell 1,429 shares of its common stock under a Form 144 notice. The sale is expected to be executed through Merrill Lynch in Washington, DC, with an aggregate market value of 247,688 and is targeted for 01/06/2026 on NASDAQ.

The shares to be sold were acquired on 01/04/2026 through stock plan activity from the issuer, with payment made on the same date. The filing also notes that 213,273,469 shares of the issuer’s securities were outstanding, providing context for the planned sale.

Insmed Inc. (INSM) reported a planned sale of company stock under Rule 144. A holder intends to sell 1,396 shares of common stock through Merrill Lynch on or about 01/06/2026 on the NASDAQ market, with an aggregate market value of $241,968.68 based on the figures shown. These shares were acquired from the issuer on 01/04/2026 through stock plan activity, with the same date listed as the payment date.

The notice also reports that during the past three months, Michael Smith sold 27,130 common shares on 11/03/2025 for gross proceeds of $4,985,054. The filing lists 213,273,469 common shares outstanding for the issuer, providing context for the size of the planned transaction.

A shareholder filed a Form 144 indicating an intent to sell 4,096 shares of common stock through Merrill Lynch on or about 01/06/2026, with the stock listed on NASDAQ. These shares were acquired on 01/04/2026 through stock plan activity from the issuer, with the same date listed as the payment date. The filing notes that common shares outstanding were 213,273,469, providing a baseline for the company’s share count.

Over the prior three months, the same seller, William Lewis, reported two additional sales of common stock: 10,699 shares on 12/18/2025 for gross proceeds of 1,786,437, and another 10,699 shares on 12/04/2025 for gross proceeds of 2,199,583. By signing the notice, the seller represents that they do not know of any material adverse information about the issuer’s current or prospective operations that has not been publicly disclosed.

Insmed’s Chief Legal Officer Michael Alexander Smith received new equity awards. On January 2, 2026, he was granted 5,293 Restricted Stock Units (RSUs), each equal to one share of common stock, under Insmed’s Amended and Restated 2019 Incentive Plan. The RSUs vest 25% on the first day of the first month following the first anniversary of the grant date, then 25% on each anniversary of that initial vesting date until fully vested. The grant increased his directly held common stock to 60,195 shares.

On the same date, he was also granted 27,600 stock options with an exercise price of $177.12 per share, expiring on January 2, 2036. These options vest 25% on the initial vesting date, with an additional 12.5% every six months thereafter until fully exercisable. Following this grant, he holds 27,600 stock options directly.

Insmed Incorporated reported topline results from its Phase 2b BiRCh study of brensocatib in patients with chronic rhinosinusitis without nasal polyps (CRSsNP) and announced that it has discontinued development of brensocatib for this indication. The 24‑week, randomized, double‑blind, placebo‑controlled study enrolled 288 patients across 104 global sites, comparing once‑daily brensocatib 10 mg, brensocatib 40 mg, and placebo, all on top of mometasone furoate nasal spray.

The primary endpoint was change from baseline in the 28‑day average daily Sinus Total Symptom Score at Week 24. Least squares mean changes were -2.44 for placebo, -2.21 for brensocatib 10 mg, and -2.33 for brensocatib 40 mg. Brensocatib was observed to be well tolerated, with similar rates of treatment‑emergent and serious adverse events across arms. Insmed also disclosed it has acquired INS1148, an investigational monoclonal antibody it plans to develop for respiratory, immunological, and inflammatory diseases with high unmet need.

Insmed Inc. (INSM) reported an insider transaction on a Form 4 filing. A company director sold 5,000 shares of Insmed common stock on November 24, 2025, identified with transaction code "S" for a sale. The shares were sold at a price of $204.58 per share in an open market transaction.

After this sale, the director beneficially owns 58,729 shares of Insmed common stock, held directly. The filing reflects a routine update to the director’s ownership position and does not report any derivative securities activity.

Insmed Inc director Leo Lee reported multiple sales of Insmed Common Stock on November 17, 2025, totaling 75,000 shares. Footnotes describe weighted average sale prices ranging from $193.00 to $197.78 per share. After these trades, Lee directly held 54,677 Insmed common shares.

Insmed Inc. (INSM) reported an insider stock sale by a company director. On 11/14/2025, the director sold 10,000 shares of common stock at a price of $195.87 per share, according to a Form 4 filing. After this transaction, the director continues to hold 63,729 shares directly. This filing simply records a change in the director’s personal holdings and does not, by itself, change the company’s operations or financial results.

Insmed Incorporated announced that the European Commission has approved its drug BRINSUPRI (brensocatib 25 mg tablets) to treat non-cystic fibrosis bronchiectasis in certain younger and adult patients. The approval covers patients 12 years of age and older who have experienced two or more exacerbations in the prior 12 months, addressing a population with recurrent respiratory flare-ups. Insmed disclosed the news in connection with a press release, which is included as an exhibit to the report.